Cutting costs on mono-resistant tuberculosis diagnosis could eventually end up being more expensive

Indian J Med Microbiol. Oct-Dec 2010;28(4):412-3. doi: 10.4103/0255-0857.71808.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Culture Media / chemistry
  • Culture Media / economics*
  • Drug Resistance, Bacterial*
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use
  • Microbial Sensitivity Tests / economics
  • Microbial Sensitivity Tests / methods
  • Mycobacterium tuberculosis / drug effects*
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Tuberculosis / diagnosis*
  • Tuberculosis / drug therapy
  • Tuberculosis / economics
  • Tuberculosis, Multidrug-Resistant / diagnosis
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / economics

Substances

  • Antitubercular Agents
  • Culture Media
  • Isoniazid
  • Rifampin